心血管疾病（CVD）是前列腺癌（PC）患者死亡的主要原因。使用促性腺激素释放激素受体 (GnRH) 激动剂或拮抗剂的雄激素剥夺疗法 (ADT) 是晚期 PC 的标准治疗方法。自 2010 年以来，美国食品和药物管理局要求 GnRH 激动剂的标签中包含有关糖尿病和某些 CVD 风险增加的警告。在这项观察性、回顾性、真实世界研究中，我们评估了 3 年内首次发生 CV 事件的时间-PC患者开始ADT，同时控制CVD病史和危险因素。使用 Kaplan-Meier 生存分析来计算首次 CV 事件发生时间的风险比 (HR)，并使用 Cox 回归来分析来自大型美国行政索赔数据集 (2010-2019) 的数据，以确定与首次 CV 事件发生时间相关的因素。 10,530 名患者中，92% 没有 CVD 病史，8% 有 CVD 病史，95% 在随访期间接触过 GnRH 激动剂。 Kaplan-Meier 分析表明，与没有 CVD 基线病史的患者相比，有 CVD 基线病史的患者在 ADT 开始后 3 年内发生 CV 事件的风险增加（HR，3.20；95% CI，2.58 至 3.96；P < 0 .0001）。在与 CV 事件可能性较高相关的协变量中，基线 CVD 病史产生的 HR 最高（2.83；95% CI，2.40 至 3.32，P < 0 .0001）。有 CVD 病史的 PC 患者发生 CV 的风险增加与无 CVD 病史的患者相比，ADT 开始后 3 年内发生的事件发生率更高。

Cardiovascular disease (CVD) is the leading cause of death among prostate cancer (PC) patients. Androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone receptor (GnRH) agonist or antagonist is the standard treatment for advanced PC. Since 2010, the US Food and Drug Administration has required labeling for GnRH agonists to include warnings about increased risk for diabetes and some CVDs.In this observational, retrospective, real-world study, we evaluated time to a first CV event within 3 years post-initiation of ADT in PC patients, while controlling for CVD history and risk factors. Data from a large administrative US claims dataset (2010-2019) were analyzed using Kaplan-Meier survival analysis to calculate the hazard ratio (HR) for time to first CV event and Cox regressions to identify factors associated with time to first CV event.Of 10,530 patients, 92% had no history of CVD, 8% had history of CVD, and 95% were exposed to a GnRH agonist during follow-up. Kaplan-Meier analysis indicated that patients with a baseline history of CVD had increased risk of CV events within 3 years of ADT initiation vs those without such history (HR, 3.20; 95% CI, 2.58 to 3.96; P < 0 .0001). Among covariates associated with higher likelihood of CV event, baseline history of CVD yielded the highest HR (2.83; 95% CI, 2.40 to 3.32, P < 0 .0001).PC patients with a history of CVD are at increased risk of a CV event within 3 years of ADT initiation compared with those with no history of CVD.